BRAF

A gene on chromsome 7q34 that encodes a protein of the raf/mil family of serine/threonine protein kinases, which plays a role in regulating the MAP kinase/ERKs-signalling pathway, affecting cell division, differentiation and secretion.

Molecular pathology
BRAF mutations are associated with cardiofaciocutaneous syndrome, which is characterised by heart defects, mental retardation and a distinctive facial appearance. Acquired BRAF mutations have been linked to non-Hodgkin lymphoma, colorectal cancer, melanoma, thyroid carcinoma, non-small cell lung carcinoma and adenocarcinoma of lung.

Mentioned in

References in periodicals archive

Recent recommendations listed 2 sets of tests: a set of essential tests (EGFR, ALK, ROS1) that can be used to direct therapy and an optional set (BRAF, RET, MET, HER2, KRAS) that can be used to direct patients toward clinical trials.

Molecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis

On multivariable analysis, V600E, but not non-V600E, BRAF mutation was correlated with worse overall survival and disease-free survival (hazard ratios, 2.76 and 2.04, respectively).

V600E BRAF Mutation Tied to Worse Survival in CRC Liver Mets; Worse overall, disease-free survival with V600E BRAF versus KRAS mutation in colorectal liver metastases

Here, we report on the results of a large-scale translational melanoma study with the primary aim of investigating the practicality of ctDNA analysis and its viability to serve as an alternative to tissue-based testing to assess BRAF mutation status.

Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy

Ideas for new treatment options for BRAF-mutated CRCs concentrate on targeting the BRAF mutation because this mutation is blamed for the bad prognosis.

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report

Mutations in the KRAS (exons 2, 3, and 4), NRAS (exons 2, 3, and 4), HRAS (exon 2), and BRAF (exon 15) of each tumor specimen were examined.

Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with [BRAF.sup.V600E] Mutation

Our attempt was to study the frequency of BRAF mutation in various thyroid diseases.

Braf mutation analysis in thyroid diseases--a study from a tertiary care hospital/centre in kerala

G12D) and BRAF mutation exon 15 codon 600 at V600E (GAG), V600D (GAT), or V600K (AAG).

Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma

The B-type Raf proto-oncogene (BRAF) encodes an enzyme that takes part in intracellular signaling and cell growth, and BRAF mutation has been frequently observed in CRC, supporting its role in tumorigenesis [4,17].

Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival